Video

Dr. Cohen on AEs Associated with BTK Inhibitors in CLL

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, co-director, Lymphoma Program, chair, Data and Safety Monitoring Committee, Winship Cancer Institute of Emory University, discusses the adverse effects (AEs) associated with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Like any anticancer therapy, BTK inhibitors carry AEs, making it important to remind patients that they must be monitored closely, Cohen says. The most significant AEs associated with BTK inhibitors include a higher incidence of bleeding and an increased risk of atrial fibrillation, Cohen explains.

Other less severe, but problematic, toxicities can include diarrhea, joint aches, headaches, and hypertension, Cohen continues. Individual agents can also lead to an increased risk of specific AEs, such as neutropenia with zanubrutinib (Brukinsa) and headaches with acalabrutinib (Calquence), Cohen says. Patients need to be aware of potential AEs in order to recognize them, Cohen concludes.

Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center